Clinical Trials Logo

Spondylarthritis clinical trials

View clinical trials related to Spondylarthritis.

Filter by:

NCT ID: NCT04853212 Recruiting - Spondyloarthritis Clinical Trials

The Role of Intestinal Microbiota Dysbiosis in the Development of Spondyloarthritis

RUMINOSPA
Start date: June 14, 2021
Phase: N/A
Study type: Interventional

The primary objective of this case-control study aims to explore the role of bacterium Ruminococcus gnavus (R. gnavus) with intestinal biopsy and faecal sampling in the initiation and the development of spondyloarthritis (SPA) in comparison with health control subjets (patients without chronic disease but have indication to digestive endoscopy).

NCT ID: NCT04846244 Active, not recruiting - Clinical trials for Axial Spondylarthritis (axSpA)

A Study of the Change in Early and Sustained Pain Control in Axial Spondylarthritis in Adult Participants Receiving Upadacitinib

UPSTAND
Start date: April 30, 2021
Phase:
Study type: Observational

Axial spondyloarthritis (axSpA) is an immune-mediated inflammatory disease primarily affecting the axial skeleton. The most frequent axSpA symptom is chronic, often inflammatory back pain (IBP) that might be difficult to distinguish from other causes of chronic back pain (CBP). Many participants report persistent pain, including back pain, which impacts disease activity and quality of life including creating burdens such as sleep disturbance, social isolation, loss of productivity, as well as anxiety and depression. This study will assess the real-world effectiveness of upadacitinib on early and sustained pain control, and the association between pain and clinical/patient-reported outcomes in axSpA participants. Upadacitinib is being developed for the treatment of axSpA. Approximately 650 adult participants with active-axSpA will be enrolled across approximately 19 countries in Europe, North America, South America, and Asia-Pacific. Participants will receive oral upadacitinib tablets as prescribed by the physician prior to enrolling in this study in accordance with the terms of the local marketing authorization and professional and reimbursement guidelines with regards to dose, population and indication. Participants will be followed for 12 months. There may be a higher burden for participants in this study compared to usual standard of care. Participants will attend regular visits per routine clinical practice. The effect of the treatment will be checked by medical assessments, checking for side effects, and questionnaires.

NCT ID: NCT04840485 Completed - Clinical trials for Ankylosing Spondylitis

Efficacy and Safety of SHR-1314 in Patients With Active Ankylosing Spondylitis

Start date: June 9, 2021
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to assess efficacy, safety, pharmacokinetics and immunogenicity of subcutaneous SHR-1314 in patients with active ankylosing spondylitis

NCT ID: NCT04821206 Recruiting - Clinical trials for Arthritis, Rheumatoid

PANLAR's Latin American Registry of Rheumatic Patients Treated With Jak Inhibitors

PREJAK
Start date: March 1, 2021
Phase:
Study type: Observational [Patient Registry]

This prospective, non-interventional, research registry is designed to study the comparative safety and comparative effectiveness of approved Jak Inhibitors treatment for RA-PsA-SpA in a cohort of patients and theirs controls cared for by rheumatologists across Latin América (LA).

NCT ID: NCT04810715 Completed - Clinical trials for Spondylitis, Ankylosing

Frequency of Pes Planus and Posterior Tibial Tendon Dysfunction in Patients With Ankylosing Spondylitis

Start date: March 1, 2021
Phase:
Study type: Observational

This investigation aims to investigate the frequency of pes planus and posterior tibial tendon dysfunction in patients with ankylosing spondylitis.

NCT ID: NCT04809168 Active, not recruiting - Clinical trials for Ankylosing Spondylitis

Neuropathic Spinal Pain in Ankylosing Spondylitis

Start date: April 6, 2021
Phase:
Study type: Observational

The aim of this study is to investigate prevalence of neuropathic spinal pain in AS patients and it's impact on sleep quality. Moreover effects of neuropathic pain on quality of life and fatigue will be assessed.

NCT ID: NCT04806867 Completed - Clinical trials for Rheumatoid Arthritis

Selection of Patients With Chronic Inflammatory Rheumatism Requiring Management During the COVID-19 Pandemia

SePaRIC
Start date: May 1, 2020
Phase:
Study type: Observational

The project proposes to evaluate a strategy for prioritizing teleconsultation for patients with chronic inflammatory rheumatic diseases during the COVID-19 pandemia. This selection will be done through telephone contact by medical students, supervised by residents and rheumatologists on a patient database. The other objectives are to assess the impact of the pandemia on the physical and mental health of patients classified as being at risk

NCT ID: NCT04798625 Active, not recruiting - Clinical trials for Rheumatoid Arthritis

Vaccine Response to COVID-19 Vaccines in Patients Using Immunosuppressive Medication

Nor-vaC
Start date: February 15, 2021
Phase:
Study type: Observational

The purpose of this study is to assess the strength and duration of the immunological response to COVID-19 vaccines in patients treated with immunosuppressive and/or immunomodulating medication for immune-mediated inflammatory diseases in rheumatology and gastroenterology and after a liver transplantation.

NCT ID: NCT04795141 Terminated - Clinical trials for Ankylosing Spondylitis

ABY-035 in the Treatment of Subjects With Ankylosing Spondylitis

Start date: August 24, 2021
Phase: Phase 2
Study type: Interventional

ABY-035-204 is a clinical study to assess the efficacy of IL-17 blocker ABY-035 in ankylosing spondylitis(AS). The primary objective is to estimate the relationship between different dose regimens of ABY-035 and clinical response as assessed by Assessment of Spondyloarthritis International Society 40 (ASAS40) response at Week 16 in subjects with active AS.

NCT ID: NCT04751396 Recruiting - Clinical trials for Rheumatoid Arthritis

Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors

Start date: April 20, 2022
Phase:
Study type: Observational

This study learn how easily patients can use an educational tool that will be created for patients with melanoma and pre-existing autoimmune diseases who receive or will receive immune checkpoint inhibitor drugs. Patients will be asked their opinions about the design, accessibility, and content of the tool. Researchers will use the information collected to improve the educational materials that will help patients make future decisions about their treatment.